Who Worked with Brian Rowan? Sales Representatives and Medical Providers Allegedly Joined Nationwide Wound-Graft Network

Prosecutors describe Alexandra Gehrke, Jeffrey King, affiliated medical businesses, unnamed sales representatives, and healthcare providers as participants within an alleged kickback-driven network targeting elderly and terminally ill patients across the United States.

PHOENIX, Arizona — Federal prosecutors investigating Brian Rowan have described an extensive commercial and medical network allegedly involving corporate executives, wound-graft marketers, medically untrained sales representatives, enrolled healthcare providers, shell-company accounts, and clinicians treating elderly patients across several American jurisdictions.

Rowan, a 47-year-old Las Vegas resident and former vice president of sales for a Texas-based wound-allograft distributor, stands accused of helping direct payments that allegedly encouraged providers and representatives to purchase exceptionally expensive amniotic products reimbursed through federal and commercial insurance programs.

The indictment publicly identifies Alexandra Gehrke and Jeffrey King as prominent participants connected with the alleged operation, while describing additional representatives, providers, company employees, and entities through generic titles because their identities were either withheld or remained outside Rowan’s charging document.

Gehrke and King previously pleaded guilty in their related prosecution and received substantial prison sentences, but Rowan remains presumed innocent of every allegation unless prosecutors prove his knowledge, intentions, participation, and responsibility through admissible evidence establishing guilt beyond a reasonable doubt.

The Indictment Identifies a Multilayered Network

The Justice Department’s official announcement concerning Rowan’s prosecution alleges that he caused hundreds of millions of dollars in unlawful kickbacks, bribes, and rebates to reach sales representatives and medical providers purchasing allografts from the company where he directed sales.

Prosecutors contend that the participating network extended from a wholesale distributor’s corporate offices toward independent marketing organizations, field representatives, enrolled Medicare providers, nurse practitioners, hospice facilities, nursing homes, assisted-living communities, billing operations, shell-company accounts, and insurers processing the resulting reimbursement claims.

That structure matters because the government does not portray Rowan as a clinician personally selecting wounds or applying grafts, but as a commercial executive who allegedly supplied the incentives, pricing information, invoice arrangements, and payment infrastructure supporting decisions made elsewhere.

The defense can challenge whether this network constituted a single criminal agreement, several independently operating businesses, or ordinary relationships among distributors, marketers, clinicians, accountants, bankers, insurers, and healthcare organizations participating within a complicated but potentially lawful marketplace.

Alexandra Gehrke Was a Central Sales Figure

The indictment identifies Alexandra Gehrke, a Phoenix-area resident, as a sales representative who co-owned or controlled Apex Mobile Medical, Apex Medical, APX Mobile Medical, and Viking Medical Consultants, organizations allegedly performing different marketing, referral, provider, and reimbursement functions.

Federal authorities say Gehrke operated Apex Medical and Viking as marketing organizations that arranged or recommended purchases of the distributor’s allografts, recruited field representatives, located prospective patients, and referred those patients toward enrolled providers applying the products.

Prosecutors allege that Rowan knew Gehrke acted as the distributor’s representative for Apex Mobile, APX, and other providers, giving her an influential position connecting corporate product sales with patient recruitment, clinical applications, provider purchases, and insurance reimbursements.

Gehrke pleaded guilty to conspiracy to commit healthcare and wire fraud during October 2024, meaning her established criminal responsibility differs fundamentally from Rowan’s current status as a charged defendant entitled to contest every disputed assertion.

Jeffrey King Allegedly Managed the Provider Side

Jeffrey King, whom court documents describe as Gehrke’s husband, initially worked as an Apex sales representative before becoming a co-owner and managing partner of APX, an enrolled Medicare provider that purchased the distributor’s allografts and submitted reimbursement claims.

Prosecutors portray King as occupying the provider-facing side of the operation, where patients identified through marketing representatives were referred toward APX and treated by contracted practitioners who allegedly applied grafts ordered through commercially driven rather than independently clinical processes.

King pleaded guilty to conspiracy to commit healthcare and wire fraud during January 2025, after authorities alleged that he helped direct clinicians to apply products even when the treatments were medically unreasonable, unnecessary, excessively large, or unsuitable for particular wounds.

The government’s narrative therefore presents Gehrke and King as complementary participants, with Gehrke allegedly directing sales recruitment and graft ordering while King helped manage the enrolled provider receiving referrals, arranging applications, and submitting insurance claims.

Gehrke and King Have Already Been Sentenced

Federal authorities announced that Gehrke received a sentence exceeding fifteen years while King received fourteen years, following guilty pleas connected with more than $1.2 billion in claims submitted toward Medicare, TRICARE, CHAMPVA, and commercial insurers.

A news report examining the national healthcare-fraud crackdown described Rowan’s alleged role within the wider enforcement action, which included accusations reaching sales executives, providers, marketers, billing personnel, and other participants across numerous medical sectors.

Gehrke was ordered to pay approximately $614.9 million in restitution and forfeit nearly $280 million, while King was ordered to pay approximately $605.7 million in restitution and forfeit more than $130 million connected with their admitted conduct.

Their guilty pleas can provide prosecutors with important documentary, financial, and testimonial evidence, although those convictions cannot substitute for independently proving Rowan’s knowledge, intent, participation, and responsibility for every charge contained within his separate indictment.

Apex Medical Allegedly Recruited Sales Representatives

Apex Medical allegedly contracted with medically untrained representatives who visited locations containing substantial elderly populations, including hospice facilities, nursing homes, assisted-living communities, and other residential settings where chronic wounds and medically vulnerable patients could frequently be found.

According to prosecutors, these representatives were instructed to identify Medicare beneficiaries with wounds at any stage, photograph and measure those wounds, obtain insurance information, arrange orders for the distributor’s allografts, and refer patients toward affiliated medical providers.

These alleged responsibilities moved far beyond conventional product education because the representatives supposedly participated in identifying patients, evaluating wound dimensions, choosing graft sizes, organizing purchases, and directing referrals despite lacking medical education or professional authority.

The defense may argue that representatives performed administrative intake, photography, logistics, or product-support services under provider supervision, requiring prosecutors to prove whether their actual conduct improperly displaced clinical judgment rather than merely supporting licensed practitioners.

Sales Representatives Allegedly Received Volume-Based Payments

The indictment alleges that representative compensation was calculated according to the quantity and dimensions of allografts purchased by recruited providers, creating progressively larger payments whenever more products or greater numbers of billable square centimeters entered the reimbursement system.

Prosecutors contend that Rowan and others paid Gehrke through Apex and Viking according to this model, while Gehrke allegedly distributed tens of millions of dollars toward additional representatives responsible for locating patients and generating product orders.

From approximately July 2022 through March 2024, the distributor allegedly transferred more than $271 million toward Gehrke-controlled organizations based upon products purchased by Apex Mobile, APX, and additional providers submitting claims toward federal or commercial insurers.

Large sales commissions remain lawful within many industries, but federal healthcare restrictions can transform compensation into prohibited remuneration when payments are knowingly offered to induce orders, purchases, referrals, or recommendations involving items reimbursed through qualifying government programs.

Representatives Allegedly Targeted Vulnerable Patients

Prosecutors claim Gehrke and King instructed representatives to visit facilities serving elderly residents, locate virtually any patient with a wound, photograph the affected area, collect measurements, obtain insurance information, and begin arranging commercially valuable allograft orders.

The indictment alleges that representatives were directed to order grafts measuring at least four centimeters by six centimeters, even when a patient’s wound was substantially smaller and less expensive product sizes remained commercially available.

Because reimbursement could increase according to the number of square centimeters applied, prosecutors may argue that ordering unnecessarily large grafts produced greater provider reimbursements, distributor revenues, representative compensation, and financial returns for organizations receiving alleged kickbacks.

Defense attorneys may examine whether larger products were sometimes clinically justified through margins, anticipated wound development, handling considerations, packaging availability, wastage rules, contamination avoidance, or professional preferences recognized within legitimate wound-care practice.

Apex Mobile and APX Submitted Insurance Claims

Apex Mobile Medical and APX Mobile Medical were enrolled Medicare providers operating from Arizona, and both organizations allegedly purchased the distributor’s allografts, arranged their application toward patients, and submitted reimbursement claims covering products and related services.

The Rowan indictment attributes approximately $1.2 billion in allegedly false claims and approximately $614 million in resulting payments toward Apex Mobile and APX between November 2022 and April 2024, although wider distributor-related billing allegedly exceeded those figures.

Prosecutors claim the submissions were fraudulent because certain products were medically unreasonable, acquired through unlawful remuneration, billed using misleading cost information, or applied after representatives rather than qualified practitioners effectively controlled ordering decisions.

Rowan’s defense may emphasize that enrolled providers, not a distributor’s sales executive, possessed direct responsibility for examining patients, documenting medical necessity, selecting treatment, reporting acquisition costs, applying products, and certifying insurance submissions as complete and accurate.

Clinicians Allegedly Applied the Products

The participating provider organizations reportedly contracted with nurse practitioners and other medical personnel responsible for applying allografts, documenting treatment, communicating with patients, and performing clinical work connected with claims submitted under enrolled provider credentials.

Prosecutors previously alleged that Gehrke and King directed contracted practitioners to disregard independent judgment and apply ordered grafts even when wounds were infected, already healed, unresponsive, excessively small, or unlikely to improve because of terminal illness and serious comorbidities.

Those allegations do not establish that every practitioner knowingly committed fraud, because clinicians may have received incomplete information, relied upon supervisors, believed products were appropriate, misunderstood reimbursement relationships, or exercised individualized medical judgment under difficult circumstances.

Determining each provider’s responsibility requires examining professional credentials, contracts, patient records, wound photographs, treatment notes, communications, payment arrangements, supervisory relationships, clinical outcomes, and whether the practitioner understood any financial incentives surrounding the product.

An Unnamed California Physician Appears in the Indictment

Rowan’s indictment identifies an individual called “Provider 1,” described only as a licensed medical doctor residing in Los Angeles and enrolled with Medicare, preserving anonymity while recounting an alleged August 2023 meeting involving Rowan and other company participants.

Prosecutors claim Rowan told the physician that federal investigators did not want providers acknowledging that they earned money from the distributor’s allografts, a statement the government may present as evidence that Rowan understood regulatory concerns surrounding provider profitability.

The defense may dispute the quotation’s context, accuracy, interpretation, completeness, or criminal significance, arguing that healthcare providers can lawfully generate earnings from covered treatment and that discussing regulatory sensitivity does not necessarily demonstrate participation within a kickback conspiracy.

Because the publicly available indictment does not identify Provider 1 by name, responsible reporting should not speculate about the physician’s identity or attach Rowan’s allegations toward unrelated Los Angeles wound-care professionals lacking documented connections.

Carlos Ching Was Charged in the Earlier APX Case

Separate public records from the earlier APX prosecution identified Carlos Ching, a medical provider accused of applying unnecessary allografts through APX, where prosecutors said approximately $87 million was billed and more than $65 million was paid during the relevant period.

Ching’s appearance within an associated APX case illustrates how the alleged network could connect field representatives, corporate marketers, enrolled provider organizations, individual clinicians, product distributors, federal healthcare programs, and private insurers through overlapping transactions.

However, Rowan’s indictment does not publicly identify Ching as a charged co-defendant, and the existence of related APX allegations should not be treated as proof that every participant belonged to precisely the same conspiracy charged against Rowan.

Legal responsibility remains individualized because prosecutors must establish what each person knew, which conduct that person performed, what payments were received, whether treatment was medically defensible, and whether the participant intentionally joined an unlawful agreement.

The Distributor Remains “Company 1” in the Indictment

Although Rowan has been publicly described as Legacy Medical Consultants’ former vice president of sales, the indictment generally refers to his employer as “Company 1,” a Texas limited liability company operating from Fort Worth as a wholesale allograft distributor.

The company allegedly acquired amniotic products manufactured from donated placental tissue, relabeled those products for commercial distribution, and charged prices reaching approximately $1,450 for every square centimeter, with some product markups allegedly exceeding two thousand percent.

High pricing and substantial markups do not independently establish criminal activity because medical-product costs may incorporate research, regulatory compliance, processing, quality assurance, sterility, storage, distribution, insurance, wastage, training, and commercial risk.

Prosecutors instead connect pricing with allegedly concealed remuneration, asserting that displayed invoice amounts overstated providers’ true costs after separate rebates, kickbacks, credits, and pass-through transfers returned significant value toward purchasers.

The Alleged Rebate Model Connected Multiple Participants

Rowan and other company personnel allegedly presented providers with rebate arrangements offering substantial economic returns whenever they purchased qualifying quantities of allografts, even though prosecutors claim providers sometimes received rebates without satisfying stated contractual thresholds.

Marketing materials allegedly compared Medicare reimbursement with discounted product costs, illustrating how a provider receiving a forty-percent rebate could retain thousands of dollars after purchasing and billing a single allograft measuring four centimeters by six centimeters.

Prosecutors may argue that these calculations transformed patient treatment into a profit formula distributed among executives, marketing organizations, field representatives, provider businesses, and clinicians, while financial incentives encouraged higher volume and larger graft dimensions.

The defense may contend that rebates, distributor commissions, promotional materials, and profitability calculations are common commercial tools, requiring proof that disputed payments were intentionally designed to induce federally reimbursed purchases or facilitate material deception.

Sham Invoices Allegedly Concealed Provider Profits

After Medicare’s contractor required providers to report complete invoice prices reflecting every discount, rebate, refund, or adjustment, prosecutors say Rowan and others authorized invoices displaying full prices without revealing the economic benefits purchasers received elsewhere.

Providers allegedly submitted those invoices when requesting reimbursement, enabling them to obtain payments based upon nominal acquisition costs while retaining profits produced through rebates or transfers that supposedly reduced their genuine net expenses.

The indictment therefore treats invoices as connective evidence linking distributor personnel, sales representatives, providers, claims administrators, financial accounts, and insurers because each document allegedly preserved the commercial appearance supporting payment.

Rowan may challenge whether he prepared particular invoices, understood provider reporting obligations, controlled claim submissions, knew how insurers calculated reimbursement, or reasonably believed that separate contractual compensation required inclusion within the applicable total-cost figure.

Shell Accounts Allegedly Replaced Visible Rebates

Prosecutors claim Rowan and others developed a new payment model after reimbursement rules made rebates more difficult to conceal, using a shell-company bank account associated with APX to move money while preserving apparently full-price invoices.

Under the alleged structure, APX transferred reimbursement proceeds toward the distributor, which deposited corresponding money into the shell-company account before approximately forty percent was returned toward APX as an allegedly unlawful purchasing inducement.

The indictment claims that APX transferred approximately $325.9 million in reimbursements toward the distributor between June and November 2023, after which approximately $130.3 million allegedly returned through the connected pass-through account.

Ordinary businesses can lawfully use special-purpose companies and controlled accounts, meaning prosecutors must demonstrate that this particular arrangement lacked genuine commercial substance and intentionally concealed remuneration influencing federally reimbursed purchasing.

Specific Transfers Connect the Alleged Participants

Among the overt acts described, prosecutors identify transfers of approximately $7.17 million and $15.3 million from the shell-company account toward APX during September and November 2023, alongside substantially larger payments toward Apex from another company account.

The indictment also describes an approximately $71.1 million transfer toward Apex during December 2023 and an approximately $81.8 million transfer during January 2024, payments prosecutors characterize as kickbacks rather than legitimate compensation.

Financial records may reveal who authorized each movement, who controlled every account, whether recipients performed genuine services, how transfers were recorded for accounting and taxation, and whether participants attempted to conceal the payment purpose.

Rowan can challenge whether individual transfers were within his authority, whether their characterization accurately reflects underlying contracts, whether he possessed required knowledge, and whether each transaction actually induced covered purchases.

Other Sales Representatives Remain Unnamed

The indictment repeatedly refers to additional distributor representatives, Apex representatives, Viking representatives, company employees, and providers without naming them, indicating that the government’s investigation reached more participants than those publicly identified within Rowan’s charging document.

Some individuals may have cooperated, testified before the grand jury, entered separate resolutions, remained under investigation, received immunity, faced charges elsewhere, or lacked sufficient evidence to support public criminal accusations.

Responsible reporting must therefore distinguish publicly documented participants from speculative connections because employment, sales activity, provider status, or association with a named organization does not automatically establish knowledge of fraud.

The unresolved identities may become clearer through subsequent court filings, witness disclosures, plea proceedings, evidentiary motions, trial exhibits, sentencing records, or additional charges filed as the wider investigation continues.

Separate Takedown Defendants Are Not Automatically Rowan Associates

The 2026 national enforcement action also charged Sandra Peters, described as an allograft sales representative, and Susie Kamien, described as a medical biller, in substantial wound-care cases announced alongside Rowan’s prosecution.

Their simultaneous inclusion within the federal takedown does not establish that either person worked with Rowan because the public Rowan indictment does not identify them among his named participants or expressly connect their charged conduct with his alleged conspiracy.

Similarly, other wound-care defendants appearing throughout Arizona, Texas, Florida, Nevada, and additional jurisdictions should not be described as Rowan co-conspirators without court documents establishing a specific transactional, corporate, communicative, or financial relationship.

This distinction protects accuracy while recognizing that federal investigators were examining a rapidly expanding national allograft marketplace containing several potentially overlapping distributors, sales organizations, providers, billing operations, and reimbursement arrangements.

Healthcare Providers Retained Independent Duties

Licensed physicians, nurse practitioners, and enrolled provider organizations remained professionally responsible for examining patients, diagnosing wounds, considering alternatives, documenting necessity, coordinating treatment, selecting appropriately sized products, supervising applications, and submitting accurate insurance claims.

That independence may strengthen Rowan’s defense if providers concealed inappropriate practices, manipulated documentation, ignored company instructions, misrepresented product costs, or applied allografts beyond anything a distant sales executive could reasonably anticipate or control.

Prosecutors may answer that professional independence does not protect executives who knowingly design compensation, invoicing, and payment structures intended to corrupt medical judgment and generate predictable claims through recruited providers.

The trial may consequently examine whether providers acted autonomously or became financially dependent participants within a system allegedly engineered to reward repeated applications, oversized products, vulnerable-patient recruitment, and concealed acquisition costs.

Hospice Facilities Were Alleged Recruitment Locations

Hospice enrollment does not make advanced wound care automatically inappropriate because terminally ill patients can require interventions reducing pain, drainage, infection, odor, exposed tissue, or other symptoms affecting comfort and dignity.

Prosecutors nevertheless allege that representatives deliberately visited hospice facilities because elderly beneficiaries with insurance coverage and persistent wounds offered continuing opportunities for expensive applications, even when meaningful healing remained clinically improbable.

Patient-specific evidence will be essential for distinguishing legitimate palliative treatment from applications allegedly driven by reimbursement, including prognosis, wound condition, infection status, circulation, prior therapy, documented progress, treatment goals, and product dimensions.

Families may also provide testimony concerning consent discussions, practitioner visits, treatment outcomes, financial disclosures, patient discomfort, whether regular physicians were consulted, and how representatives first identified prospective recipients.

Communications Could Define Rowan’s Relationships

Emails, text messages, spreadsheets, commission schedules, meeting records, invoice requests, provider profitability calculations, bank instructions, sales contests, account rankings, and compliance discussions may reveal how Rowan communicated with Gehrke, King, representatives, and providers.

The indictment describes a December 2021 spreadsheet allegedly calculating provider profits and representative commissions, along with Rowan’s September 2023 message increasing compensation for Apex and Gehrke toward sixty percent on qualifying new orders.

Prosecutors also cite Rowan’s favorable response toward promotional flyers advertising a sales contest that included private airfare and dinner with company executives, evidence they may use to demonstrate his familiarity with aggressive representative incentives.

Defense counsel may argue that commercial enthusiasm, commission discussions, travel rewards, and sales growth remain lawful unless prosecutors connect them convincingly with prohibited referrals, medically unnecessary applications, deceptive invoices, or concealed kickbacks.

Gehrke and King Could Become Important Witnesses

Because Gehrke and King have pleaded guilty and received sentences, prosecutors may seek their testimony concerning negotiations with Rowan, distributor payment structures, sales instructions, shell accounts, invoices, provider relationships, and their understanding of the alleged agreement.

Cooperating witnesses can provide direct evidence unavailable through financial documents alone, but their testimony may face searching cross-examination concerning plea benefits, sentencing expectations, prior dishonesty, personal responsibility, selective memory, and efforts to reduce blame.

Rowan’s attorneys may argue that convicted participants possess powerful incentives to portray him as an organizer, while prosecutors may answer that communications, transfers, and business records independently corroborate important portions of their accounts.

Jurors would ultimately evaluate credibility by comparing testimony against contemporaneous documents, account records, device evidence, provider statements, meeting schedules, reimbursement data, and explanations offered before participants understood their potential criminal exposure.

Lawful Privacy Planning Cannot Obscure Relationships

Responsible international privacy and relocation planning can protect legitimate personal security, residential confidentiality, family continuity, and financial organization, but it cannot lawfully conceal witnesses, disputed proceeds, beneficial owners, evidence, or assets subject to judicial authority.

Anyone confronting comparable federal allegations should consult qualified criminal, healthcare, forfeiture, regulatory, employment, and tax counsel before transferring property, contacting potential witnesses, reorganizing companies, opening foreign accounts, or modifying relevant records.

Even ordinarily lawful transactions can attract heightened scrutiny when completed through nominees, relatives, unfamiliar entities, digital assets, unexplained loans, or international accounts after investigative contact or criminal charges become reasonably foreseeable.

Legitimate privacy preserves truthful disclosure to courts, banks, regulators, insurers, and investigators with lawful authority, while criminal concealment depends on deception, destruction, fabrication, intimidation, disguised ownership, or obstruction.

Cross-Border Records Must Preserve the Complete Story

Compliant cross-border risk-management services should preserve verifiable relationships among identity, beneficial ownership, employment, compensation, taxation, corporate operations, banking activity, insurance, real estate, litigation disclosures, and every material international transfer.

For Rowan and any alleged associate, complete documentation could distinguish legitimate compensation, independent investments, lawful loans, earlier savings, genuine services, and ordinary business payments from money prosecutors characterize as kickbacks or healthcare-fraud proceeds.

Backdated contracts, deleted messages, fictional consulting work, inconsistent tax reporting, nominee ownership, circular transfers, unexplained companies, or sudden restructuring could weaken legitimate defenses and generate additional allegations concerning obstruction or concealment.

A defensible account requires transaction-by-transaction evidence showing where each payment originated, why every recipient received it, what services were performed, how compensation was reported, and what decision each participant understood the payment would influence.

The Government Must Prove Rowan’s Personal Agreement

Gehrke’s and King’s guilty pleas do not establish that Rowan knowingly joined their conspiracy because criminal responsibility cannot be transferred automatically through business relationships, corporate hierarchy, compensation, association, or participation within the same commercial marketplace.

Prosecutors must demonstrate that Rowan understood the unlawful objectives, intentionally participated through payments or deception, recognized the connection with federally reimbursed products, and caused or assisted particular conduct advancing the charged agreement.

Rowan may contend that independent providers-controlled patients and claims, company lawyers or advisers reviewed payment structures, representatives exceeded authorized responsibilities, and ordinary commercial practices were later characterized as fraudulent through hindsight.

The government may counter with emails, payment records, invoice instructions, profitability spreadsheets, shell-account transfers, provider meetings, compensation changes, and witness testimony allegedly showing knowledge reaching far beyond conventional sales management.

The Known and Unknown Participants Define the Case

Public records presently identify Rowan, Gehrke, King, Apex Medical, Viking Medical Consultants, Apex Mobile Medical, APX Mobile Medical, an unnamed California physician, additional unnamed representatives, contracted practitioners, and unidentified company personnel within the alleged network.

That list may expand as federal prosecutors disclose witnesses and exhibits, but accuracy requires recognizing the differing legal status of every participant because some pleaded guilty, some were separately charged, some remain unnamed, and others may never face prosecution.

The government portrays these relationships as an integrated nationwide operation connecting extraordinary distributor pricing, representative commissions, provider kickbacks, vulnerable-patient recruitment, medically unnecessary applications, misleading invoices, shell accounts, and immense insurance reimbursements.

Rowan’s defense may portray the same relationships as ordinary commercial and clinical interactions among independent organizations whose members possessed different information, responsibilities, professional duties, and interpretations of complicated reimbursement requirements.

Until Rowan enters a guilty plea or a jury returns a conviction, every allegation concerning his coordination with Gehrke, King, sales representatives, medical providers, shell companies, and company personnel remains disputed and protected by the presumption of innocence.

The eventual proceeding must determine whether Rowan was merely a successful sales executive working with independent customers or a knowing organizer who allegedly connected representatives and providers through financial incentives capable of overriding patient welfare and lawful reimbursement rules.